Sanofi (NASDAQ:SNY) Given Average Rating of “Buy” by Brokerages

Shares of Sanofi (NASDAQ:SNY) have earned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $62.50.

Several analysts have issued reports on the company. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 price target for the company. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $54.91 on Friday. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The firm has a market capitalization of $139.35 billion, a price-to-earnings ratio of 22.05, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $55.03 and a 200 day moving average of $52.85.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Abel Hall LLC raised its position in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock valued at $530,000 after buying an additional 194 shares during the last quarter. Providence Capital Advisors LLC increased its holdings in Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after acquiring an additional 201 shares during the last quarter. Keudell Morrison Wealth Management increased its holdings in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after acquiring an additional 217 shares during the last quarter. Bailard Inc. lifted its stake in Sanofi by 1.4% in the 4th quarter. Bailard Inc. now owns 16,359 shares of the company’s stock worth $789,000 after purchasing an additional 220 shares in the last quarter. Finally, Old Port Advisors boosted its holdings in shares of Sanofi by 0.6% during the 4th quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after purchasing an additional 232 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.